Russia-linked hackers are targeting Signal users. These attacks exploit user trust through phishing. They trick people into revealing accou...

Smart investors keep cash reserves. This 'dry powder' allows quick action during market dips. It provides flexibility to buy assets at lowe...

Moreno Valley fire: Two fast-moving wildfires erupted Friday in Southern California, forcing rapid evacuations in parts of Moreno Valley an...

Moxie Marlinspike, who will remain on Signal's board, said he is scouting for candidates for the permanent CEO position.

Like most companies that were founded at the time, Acton says WhatsApp was initially a shot in the dark.

WhatsApp co-founder talks about why he feels Big Tech is culpable for the decline of privacy.

Acton said the Indian market has "completely exceeded all expectations" and the growth in the past few days has driven the company to add c...

Brian Acton, co-founder of WhatsApp, left Facebook in 2017 and in 2018 co-founded Signal which is now being considered the gold standard of...

Signal App is considered the gold standard for privacy by journalists and whistleblowers. WhatsApp, meanwhile, wants to share significantly...

It seems like Acton is still standing by his last year’s war cry, ‘#DeleteFacebook’.

The comment from a former Facebook insider is a particularly personal blow to the world's largest social network as it struggles to stem a ...

Acton was in New Delhi & met Ravi Shankar Prasad, who described him as a "fine mind in the field of Information technology."

Highlighting the country's importance, Acton said WhatsApp hopes to contribute more to "India's vision for digital commerce in future".

Trak N Tell provides vehicle telematics solutions, which claims to allow for predictive engine failure, preventive maintenance notification...

Eureka Forbes has also thrown their hat into ring with purification technology and this product is useful.

Instead of moping around and wallowing in misery of rejection, Acton sprang into action.

The tests will initially be only for cancer patients and Mr Saxena’s company, Acton Biotech, plans to cover other diseases later.